Obesity and metabolic disorders INTRODUCTION The increasing incidence of obesity and its metabolic sequelae, including type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and cardiovascular disease (CVD), continues to exert a huge clinical and socioeconomic burden worldwide [1,2]
Pending regulatory approval, Novo Nordisk announced that semaglutide could become the first oral formulation of a glucagon-like peptide-1 (GLP-1) indicated for chronic weight management
During the consultation, our Greeley-based providers evaluate your entire health profile to recommend the most suitable plan
As a GLP-1 receptor agonist, Semaglutide activates receptors in the brain that are in charge of hunger and satiety
Everyone responds differently to supplements based on their health, current conditions, and specific needs